Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.
Katodritou E, Terpos E, Kelaidi C, Kotsopoulou M, Delimpasi S, Kyrtsonis MC, Symeonidis A, Giannakoulas N, Stefanoudaki A, Christoulas D, Chatziaggelidou C, Gastari V, Spyridis N, Verrou E, Konstantinidou P, Zervas K, Dimopoulos MA.
Katodritou E, et al. Among authors: zervas k.
Am J Hematol. 2014 Feb;89(2):145-50. doi: 10.1002/ajh.23600. Epub 2013 Nov 21.
Am J Hematol. 2014.
PMID: 24123068
Free article.